Misdiagnosing of SCPCa with high-grade acinar adenocarcinoma occurs commonly.
While the incidence of the SCPCa is 0.5-2% in patients who underwent prostate biopsies, this incidence increases up to 10-20% in autopsy series.
The neoplastic cells had scanty cytoplasm, hypercromatic nucleus and were being island [Figure 1].
Tumor cells stained positive with synaptophysin in histochemical study [Figure 2].
Finally, SCPCa is a very rare entity in daily urology practice.
The patients may present with different signs of syndromes.
Immunohistochemical studies can be helpful for distinguishing SCPCa from poorly differentiated adenocarcinomas.
Immunohistochemical panel includes PSA, prostate specific acid phosphatase, P501s, CD 56, and neuroendocrine markers.
Med J DY Patil Univ [serial online] 2015 [cited 2019 Sep 6];4-6. 2015/8/2/234/153174 Clinical presentations of these tumors include obstructive, neurologic and constitutional symptoms such as bone pain, abdominal pain, hematochezia, hematuria, and paraneoplastic syndromes such as adrenocorticotropic hormone (ACTH) secretion, inappropriate antidiuretic hormone secretion, and myasthenic syndromes.
A 65-year-old man presented with gross hematuria during the 1 month.